COMparison of Short versus long term duration of Antimicrobial Therapy for the treatment of Stenotrophomonas maltophilia pneumonia: COMSAT Study

France Carriere B.Sc. (Pharm.); Greg Egan Pharm D.; Vincent Mabasa Pharm D.

Background

- Stenotrophomonas maltophilia (S. maltophilia) is a gram-negative bacilli associated with opportunistic infections with high morbidity and mortality
- The most common manifestation is pneumonia (PNA)
- Selecting appropriate antibiotic (abx) treatment and duration is a challenge as S. maltophilia exhibits multi-drug resistance
- The drug of choice is co-trimoxazole (12.5 20 mg/kg/day of trimethoprim component in divided doses), and most cases are treated for 14-21 days or longer
- Because of a lack of controlled clinical trials, treatment duration is largely based on anecdotal evidence and case reports

Objectives

 To describe the differences between two patient groups with pneumonia caused by *S. maltophilia;* treatment with **short course** antibiotics (14 days or less) or treatment with **long course** antibiotics (15 days or more)

Methods

- Study Design: Retrospective cohort study
- Inclusion Criteria: All adult (>18 year old) patients admitted to SMH, BUH, or ARH from Jan 2011 to July 2014 with a diagnosis (dx) of PNA and a positive sputum culture for *S. maltophilia*
- Exclusion Criteria: Less than 3 days of antibiotic therapy completed, pregnancy
- Primary Outcome: Recurrence rate †
- Secondary Outcomes:
- Clinical Cure ‡
- In-hospital mortality
- Length of hospital stay (after PNA dx)
- Statistical Analysis: Chi Squared and Student's T-test

Figure 1: Patient Flowchart




Table 1: Baseline Characteristics Short Long **Patient Characteristics** course course (No. (%) or mean \pm SD) N = 70N = 3571 ± 11.8 67 ± 14.7 Age, years 46 (66) 20 (57) Sex, male **Pre-existing condition** 46 (66) 20 (57) Cardiac 16 (23) 14 (40) Diabetes Pulmonary 37 (53) 20 (57) 6 (9) Cancer 67 ± 20.3 72 ± 20.9 Weight, kg Mechanical ventilation 54 (77) 25 (71) Location in hospital, ICU 49 (70) 25 (71) 22 (63) Other organism in sputum 33 (47) **Concurrent infection** 24 (69) 40 (57) 30 (86) Concurrent antibiotic use 57 (81) Clinical criteria for PNA dx 37.5 ± 0.8 37.4 ± 0.9 Temperature °C WBC count x 10⁹ 13.8 ± 6.5 16.8 ± 9.8 Infiltrates on CXR 62 (93) 34 (97) Antibiotic use in last 15 days 66 (94) 34 (97) Appropriate empiric dose 50 (71) 30 (86) 156 ± 193 85 ± 77 Length of stay*, days Length of Ventilation*, days 158 ± 209 52 ± 76 10 ± 2.6 Treatment Duration*, days 20 ± 5.3

Table 2: Outcomes					
Event (No. (%) or mean±SD)	Short course	Long course	P- value		
Primary Outcome					
Recurrence [†]	10 (14)	5 (14)	1.0		
Secondary Outcomes					
Clinical cure [‡]	50 (71)	27 (77)	0.533		
In-hospital mortality	31 (44)	11 (31)	0.205		
Length of stay, days	51 ± 76	112 ± 176	0.055		

Definitions

*Statistically significant

† **Recurrence**: PNA caused by the same pathogen at least 72 hours (but no more than 30 days) after resolution of the original PNA

*Clinical cure: resolution of signs and symptoms of PNA compared with baseline, no requirement for additional antibiotic treatment












Table 3: Analysis Based on Recurrence					
Patient Characteristic (No. (%) or mean ± SD)	Recurrence N = 15	No Recurrence N = 59	P-value		
Age, years	74±11	67±14	0.083		
Location in hospital – ICU*	13 (87)	33 (56)	0.028		
Mechanical Ventilation	13 (87)	39 (66)	0.120		
Length of Stay, days*	175 ± 113	97 ± 131	0.032		

*Statistically significant

Limitations

- Retrospective study design
- Evaluation of clinical outcomes based on documentation in chart
- Sample size of convenience
- Increased risk of type II error
- Many patients had co-isolates in sputum
- It is unknown if *S. maltophilia* was the pathogen or if it was a colonizer
- Patients who died between day 3 and 14 of the antibiotic course were included in the short course group

Conclusion

- There is no difference in recurrence rate between short or long course treatment
- One third of patients treated with co-trimoxazole received sub-therapeutic doses
 - There is a need for increased education and awareness
- Patients with longer durations of stay and prolonged mechanical ventilation were treated with longer courses of antibiotics
- The patient's clinical status influences the clinician's choice of therapy duration
- Larger, prospective studies specific to S. maltophilia are needed to determine optimal treatment duration

Acknowledgements: Elaine Tung BSc. & Jennifer Jun BSc. for their contribution to data collection

